AbbVie (ABBV) said late Monday it expects Q2 results to include acquired in-process research and development and milestone expense of $291 million before tax, an impact of $0.17 to both GAAP and non-GAAP EPS.
For 2026, AbbVie said it now expects adjusted EPS $13.91 to $14.11, including the Q2 impact of IPR&D and milestones expense. It now expects Q2 adjusted EPS of $3.57 to $3.61.
The company said its previous 2026 guidance from April 29 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the Q1.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.